



Practitioner's Docket No. 2002DE315

IPW
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re application of: Richard Wisdom

Application No.: 10/734,527

Group No.: 1651

Filed: December 12, 2003

For: Method for the production of (1S, 4R)-(-)-4-Hydroxy cyclopent-2-enyl esters

Commissioner for Patent
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

CERTIFICATION UNDER 37 C.F.R. Sections 1.8(a) and 1.10*

*(When using Express Mail, the Express Mail label number is mandatory;
Express Mail certification is optional.)*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. section 1.8(a)

37 C.F.R. section 1.10*

with sufficient postage as first class mail. as "Express Mail Post Office to Address" Mailing Label No. _____ (mandatory)

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office (703) _____.
Date: June 4, 2004


Signature

Jackie L. Wise
(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b).
"Since the filing of correspondence under [section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.



Applicant Richard Wisdom

Serial No. 10/734,527

Page 2

Dear Sir:

In accordance with the duty of disclosure provisions of 37 CFR §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the subject application. No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than search report(s) from a counterpart foreign application or a PCT International Search Report, if submitted herewith).

1. Enclosures accompanying this Information Disclosure Statement are:
 - 1a. Form PTO-1449.
 - 1b. Copies of Information Disclosure Statement citations.
 - 1c. PCT Search Report
 - 1d. Copies of Co-pending U.S. Applications.
2. This Information Disclosure Statement is filed under 37 CFR §1.97(b) with the filing of the U.S. patent application. Accordingly, no fee or §1.97(e) Statement is required.
3. This Information Disclosure Statement is filed under 37 CFR §1.97(b) before the latter of three months after the U.S. patent application filing date or the first Office Action on the merits. Accordingly, no fee or §1.97(e) Statement is required.
4. This Information Disclosure Statement is filed under 37 CFR §1.97(c) after the first Office Action on the merits, but before a Final Office Action or a Notice of Allowance. The \$180.00 fee set forth in 37 CFR §1.17(p) in accordance with 37 CFR §1.97(c) is to be charged to Deposit Account No. 03-2060.
5. This Information Disclosure Statement is filed under 37 CFR §1.97(e) in that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Accordingly, no fee is required.
6. This Information Disclosure Statement is filed in conjunction with a Request For Continued Examination. Accordingly, no fee or §1.97(e) Statement is required.

7. The English language documents identified by reference in the TRANSLATION Section of the foreign patents list of the attached 1449 Form are believed to be a concise statement, or the equivalent or substantial equivalent to the foreign language documents cited in the attached 1449 Form.
8. In addition to the documents cited, the Office's attention is directed to the following co-pending U.S. Application Serial Number(s), copies of which are attached for the convenience of the Office:
9. The DD 264707, DD 290663, DD 293136 & DD 290662 references disclose that the group of Theil has worked with pancreatin/porcine pancreatic lipase, but has also screened enzymes from mucor sp. (in house strain), Pseudomonas sp. (Amano PS), Lipozyme (Mucor miehi) and Candida sp. (382) for an enzyme to selectively acetylate cis-cyclopent-1-ene-3,5,-diol.

Respectfully submitted,



Anthony A. Bisulca
Registration No. 40,913

CUSTOMER NO. 25,255

Clariant Corporation
Industrial Property Department
4000 Monroe Road
Charlotte, North Carolina 28205
Telephone: 704/331-7151
Facsimile: 704/331-7707

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 2002DE315	SERIAL NO. 10/734,527
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b))		APPLICANT: Richard Wisdom	
		FILING DATE: 12/12/03	GROUP: 1651

OTE
JUN 07 2004
USPTO TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

Examiner Initial		Patent Number	Issue Dte	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	6,448,051	9/10/02	Bastawade et al.			
	AB	4,618,690	10/21/86	Schneider et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN APPLICATION

		DOCUMENT NUMBER	PUB. DATE	COUNTRY			TRANSLATION
	BA	DD283136	8/22/91	Germany			See IDS
	BB	DD290663	6/6/91	Germany			See IDS
	BC	DD290662	6/5/91	Germany			See IDS
	BD	DD264707	2/8/89	Germany			See IDS

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication**)

CA		Nara et al., "Synthesis of Optically Active Compounds by the Novel use of Meso-compounds - 1. Efficient Synthesis of Two Structural Types of Optically Pure Prostaglandin Intermediates", Tetrahedron, Vol. 36, pp. 3161 to 3170 (1980)
CB		Harre et al. "4-Oxo-2-cyclopentyl Acetates - A Synthetic Intermediate", Agnew. Chem. Int. Ed. Engl. 21; pp. 480-492 (1982)
CC		Johnson et al., "A Two-Step, Three Component Synthesis of PGE, :Utilization of a-Iodoenones in Pd(0)-Catalyzed Cross-Coupling of Organoboranes" J. Am. Chem. Soc.; pp. 11014-11015(1993)
CD		Deardoff et al., "A Palladium-Catalyzed Route to Mono- and Diprotected Cis-2-cyclopentene-1,4 Diols", Tetrahedron Letters, Vol. 26, No. 46, pp. 5615-5618 (1980)
CE		Laumen et al., "Enzymatic Hydrolysis of Prochiral Cis-1,4-Diacyl-2-cyclopentenediols; Preparation of (1S, 4R)-and (1R, 4S)-4-Hydroxy-2-cyclopentenyl derivatives, Versatile Building Blocks for Cyclopentanoid Natural Products", Tetrahedron Letters, Vol. 25, No. 51, pp. 5875-5878 (1984)
CF		Theil et al., "Lipase-Catalyzed Transesterification of meso-Cyclopentane Diols," Tetrahedron, Vol. 47, No. 36, pp. 7569-7582 (1991)
CG		Jommi et al., "Enantioselective Synthesis of 3(S)-Actoxy-5-(R)-Hydroxycyclopent-1-Ene by an Enzymatic Transesterification in Organic Solvents," Gazzetta Chimica Italiana, Vol. 118, pp. 863-864 (1998)
CH		Ghorpade et al., "Desymmetrization of meso-cyclopenten-cis-1,4-diol to 4-(R)-hydroxycyclopent-2-en-1(S)-acetate by irreversible transesterification using Chrazyme®, " Tetrahedron Assymetry, Vol. 10, pp. 891-899 (1999)
CI		Johnson et al. "Enzymatic Asymetrization of meso-2-Cycloalken-1,4-diols and Their Diacetates inorganic and Aqueous Media," Tetrahedron Letters, Vol. 33, No. 48, pp. 7287-7290 (1992)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	